Evidence map›Paper›PMID 34998434›Full record

ArticleHereditas2022

Identification of a five-miRNA signature as a novel potential prognostic biomarker in patients with nasopharyngeal carcinoma.

Bo Tu, Ling Ye, Qingsong Cao, Sisi Gong, Miaohua Jiang, Hui Li

Abstract read
In one paragraph

Article in Hereditas, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bo Tu *Department of Otorhinolaryngology and Head Neck Surgery, The first affiliated hospital of Jinan University, Guangzhou, 510630, Guangdong, China.
Ling Ye *Department of oncology, The first affiliated hospital of Jinan University, Guangzhou, 510630, Guangdong, China.
Qingsong CaoDepartment of Otorhinolaryngology and Head Neck Surgery, The first affiliated hospital of Jinan University, Guangzhou, 510630, Guangdong, China.
Sisi GongDepartment of Otorhinolaryngology and Head Neck Surgery, The first affiliated hospital of Jinan University, Guangzhou, 510630, Guangdong, China.
Miaohua JiangDepartment of Otorhinolaryngology and Head Neck Surgery, The first affiliated hospital of Jinan University, Guangzhou, 510630, Guangdong, China.
Hui LiDepartment of Otorhinolaryngology and Head Neck Surgery, The first affiliated hospital of Jinan University, Guangzhou, 510630, Guangdong, China. huilidoct@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMicroRNAs (miRNAs) are involved in the prognosis of nasopharyngeal carcinoma (NPC). This study used clinical data and expression data of miRNAs to develop a prognostic survival signature for NPC patients to detect high-risk subject.

resultsWe identified 160 differentially expressed miRNAs using RNA-Seq data from the GEO database. Cox regression model consisting of hsa-miR-26a, hsa-let-7e, hsa-miR-647, hsa-miR-30e, and hsa-miR-93 was constructed by the least absolute contraction and selection operator (LASSO) in the training set. All the patients were classified into high-risk or low-risk groups by the optimal cutoff value of the 5-miRNA signature risk score, and the two risk groups demonstrated significant different survival. The 5-miRNA signature showed high predictive and prognostic accuracies. The results were further confirmed in validation and external validation set. Results from multivariate Cox regression analysis validated 5-miRNA signature as an independent prognostic factor. A total of 13 target genes were predicted to be the target genes of miRNA target genes. Both PPI analysis and KEGG analysis networks were closely related to tumor signaling pathways. The prognostic model of mRNAs constructed using data from the dataset GSE102349 had higher AUCs of the target genes and higher immune infiltration scores of the low-risk groups. The mRNA prognostic model also performed well on the independent immunotherapy dataset Imvigor210.

conclusionsThis study constructed a novel 5-miRNA signature for prognostic prediction of the survival of NPC patients and may be useful for individualized treatment of NPC patients.

Indexed as

MicroRNAsNasopharyngeal NeoplasmsBiomarkers, TumorGene Expression Regulation, NeoplasticHumansNasopharyngeal CarcinomaPrognosisBiomarkers, TumorMicroRNAsGEOKEGGmiRNANasopharyngeal carcinomaPrognostic

Identifiers

PMID34998434
PMCPMC8742958

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.